Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Sees Significant Increase in Short Interest

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) saw a significant growth in short interest in August. As of August 14th, there was short interest totaling 7,083 shares, a growth of 70.6% from the July 30th total of 4,153 shares. Based on an average trading volume of 848 shares, the short-interest ratio is currently 8.4 days. Currently, 0.7% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Addex Therapeutics in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Addex Therapeutics currently has an average rating of “Sell”.

Addex Therapeutics Price Performance

Shares of ADXN stock traded down $0.22 during trading hours on Tuesday, hitting $3.70. The stock had a trading volume of 18,943 shares, compared to its average volume of 62,392. The firm has a market capitalization of $4.55 million, a PE ratio of -0.62 and a beta of 1.50. The stock’s 50 day moving average is $5.56 and its 200 day moving average is $6.33. Addex Therapeutics has a twelve month low of $3.68 and a twelve month high of $12.05.

About Addex Therapeutics

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.